ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

IMUX Immunic Inc

1.33
0.00 (0.00%)
Pre Market
Last Updated: 04:24:40
Delayed by 15 minutes
Company Name Stock Ticker Symbol Market Type
Immunic Inc IMUX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.00% 1.33 04:24:40
Open Price Low Price High Price Close Price Prev Close
1.33
more quote information »

Recent News

Date Time Source Heading
3/18/20248:51IHNWFeaturedElevai Labs Launches E-commerce Portal to Support Rapid Growth as Stem Cell Exosome Disruptor in the $19.7 Billion Global Physician Dispensed Cosmeceutical Market
3/18/20248:09IHNWFeaturedProspera Energy Inc. Announces a 508% increase in the 2023 Proven Developed Producing (PDP) Reserve Valuation
3/08/202416:05EDGAR2Form 8-K - Current report
3/07/202406:30PRNUSImmunic to Participate in Investor and Scientific..
3/06/202421:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
3/06/202421:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
3/06/202421:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
3/06/202421:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
3/06/202421:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
3/06/202421:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/29/202406:30PRNUSImmunic Presents Data From Phase 2 CALLIPER and CALVID-1..
2/22/202406:38EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
2/22/202406:35EDGAR2Form 8-K - Current report
2/22/202406:30PRNUSImmunic, Inc. Reports Year End 2023 Financial Results and..
2/15/202406:30PRNUSImmunic, Inc. to Announce Financial Results for the Year..
2/14/202416:05EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
2/14/202408:47EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
2/14/202407:55EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
2/13/202416:36EDGAR2Form S-3 - Registration statement under Securities Act of..
2/05/202408:30EDGAR2Form DEF 14A - Other definitive proxy statements
2/01/202406:30PRNUSImmunic to Participate in Investor and Scientific..
1/24/202417:05EDGAR2Form PRE 14A - Other preliminary proxy statements
1/19/202416:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
1/19/202416:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
1/19/202416:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
1/19/202416:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
1/19/202416:05EDGAR2Form D - Notice of Exempt Offering of Securities
1/16/202416:12EDGAR2Form SC 13G - Statement of acquisition of beneficial..
1/10/202409:00EDGAR2Form SC 13G - Statement of acquisition of beneficial..
1/05/202406:41EDGAR2Form 8-K - Current report
1/05/202406:35PRNUSImmunic Highlights 2023 Accomplishments and Upcoming..
1/05/202406:30PRNUSImmunic, Inc. Announces Private Placement of up to $240..
12/21/202308:30EDGAR2Form 8-K - Current report
11/22/202316:20EDGAR2Form S-3 - Registration statement under Securities Act of..
11/21/202306:30PRNUSImmunic Receives Notice of Allowance for United States..
11/14/202306:38EDGAR2Form 8-K - Current report
11/14/202306:30PRNUSImmunic, Inc. Reports Third Quarter 2023 Financial Results..
11/07/202306:30PRNUSImmunic to Announce Financial Results for the Third Quarter..
11/02/202306:30PRNUSImmunic Receives Notice of Allowance for United States..
10/26/202306:30PRNUSImmunic to Participate in Scientific and Industry..
10/18/202316:05EDGAR2Form 8-K - Current report
10/16/202306:30PRNUSImmunic Presents Data From Phase 2 CALDOSE-1 Trial of..
10/15/202306:30PRNUSImmunic Presents Data From Phase 1b Clinical Trial of..
10/11/202306:30PRNUSImmunic Presents Data From Phase 2 EMPhASIS Trial of..
10/10/202308:48EDGAR2Form 8-K - Current report
10/09/202316:01PRNUSImmunic Reports Positive Interim Data from Phase 2 CALLIPER..
10/04/202306:30PRNUSImmunic to Participate in Scientific Conferences in October
9/06/202306:30PRNUSImmunic to Participate in Industry and Investor Conferences..
8/21/202306:30EDGAR2Form S-8 - Securities to be offered to employees in employee..
8/17/202306:30PRNUSImmunic Completes Enrollment of Its Phase 2 CALLIPER Trial..
8/03/202306:48EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
8/03/202306:44EDGAR2Form 8-K - Current report

Your Recent History

Delayed Upgrade Clock